Loading...
Cancer-selective targeting of the NF-κB pathway via GADD45β/MKK7 inhibition: results from the phase I trial of the first-in-class inhibitor, DTP3, in patients with relapsed or refractory multiple myeloma
Chaidos, A. Potolidis, D. Cornice, J. Auner, H. Acton, G. Bygrave, C. Cook, G. Popat, R. Davies, A. Parrish, C.
Chaidos, A.
Potolidis, D.
Cornice, J.
Auner, H.
Acton, G.
Bygrave, C.
Cook, G.
Popat, R.
Davies, A.
Parrish, C.
Abstract
Authors
Chaidos, A.
Potolidis, D.
Cornice, J.
Auner, H.
Acton, G.
Bygrave, C.
Cook, G.
Popat, R.
Davies, A.
Parrish, C.
Atta, M.
Linton, K.
Smith, D.
Fox, C.
McNeish, I.
Hadley, E.
Del Peral, E. F. M.
Pellegatti, M.
Adams, N.
Chau, A.
Nnebedum, P.
Capece, D.
Verzella, D.
D'Andrea, D.
Rekowski, J.
Yap, C.
Tornatore, L.
Franzoso, G.
Potolidis, D.
Cornice, J.
Auner, H.
Acton, G.
Bygrave, C.
Cook, G.
Popat, R.
Davies, A.
Parrish, C.
Atta, M.
Linton, K.
Smith, D.
Fox, C.
McNeish, I.
Hadley, E.
Del Peral, E. F. M.
Pellegatti, M.
Adams, N.
Chau, A.
Nnebedum, P.
Capece, D.
Verzella, D.
D'Andrea, D.
Rekowski, J.
Yap, C.
Tornatore, L.
Franzoso, G.
Description
Date
2025
Publisher
Collections
Files
Loading...
Found from Unpaywall
Adobe PDF, 175.59 KB
Keywords
Type
Article
Citation
Chaidos A, Potolidis D, Cornice J, Auner H, Acton G, Bygrave C, et al. Cancer-selective targeting of the NF-κB pathway via GADD45β/MKK7 inhibition: results from the phase I trial of the first-in-class inhibitor, DTP3, in patients with relapsed or refractory multiple myeloma. Blood. 2025 NOV 3;146.